Discovering New Cancer Treatments with ISCA1 (G81689)

Target Name: ISCA1

NCBI ID: G81689

Discovering New Cancer Treatments with ISCA1

The Institute of Cancer Research (ICR) has made significant contributions to the understanding of cancer biology, and the discovery of new treatments. One of the promising areas of research at the ICR is the use of small molecules, also known as drugs, to treat cancer. One of the focus areas of the ICR is the development of drugs that target the protein ISCA1 (ISCA1_HUMAN), and this article will explore this protein and its potential as a drug target.

The ISCA1 Protein

ISCA1 (Integrin-like Scaffold protein 1) is a transmembrane protein that is expressed in a wide range of tissues, including blood vessels, tissues, and organs. It is a member of the integrin family, which is a large family of transmembrane proteins that play a critical role in cell-cell and cell-extracellular interactions. ISCA1 is involved in many different processes in the body, including cell adhesion, migration, and invasion.

One of the most significant functions of ISCA1 is its role in cell adhesion. ISCA1 is involved in the formation of tight junctions, which are specialized junctions that form between adjacent cells and help to maintain tissue structure and function. ISCA1 is also involved in the regulation of cell migration and the invasive properties of cancer cells.

In addition to its role in cell adhesion and migration, ISCA1 is also involved in the regulation of cell survival. Studies have shown that ISCA1 plays a critical role in the regulation of cell cycle progression, and that it is involved in the formation of drug resistance in cancer cells.

The Potential As a Drug Target

The potential of ISCA1 as a drug target is significant due to its involvement in so many different processes in the body. ISCA1 is a protein that is expressed in high levels in many different types of cancer, and it is involved in many of the processes that are associated with cancer progression.

One of the key advantages of ISCA1 as a drug target is its stability. Unlike many other proteins, which can be easily broken down by enzymes, ISCA1 is resistant to degradation and is expressed in high levels in many different types of cancer. This stability makes it an attractive target for small molecules that can be used to inhibit its activity.

Another advantage of ISCA1 is its involvement in many different processes in the body. This makes it an attractive target for drugs that can act on multiple pathways and mechanisms. This can help to increase the effectiveness of the drug and reduce the risk of side effects.

In addition to its potential as a drug target, ISCA1 is also a potential biomarker. The expression of ISCA1 is often increased in many different types of cancer, and it has been used as a biomarker for the diagnosis and prognosis of many different types of cancer . This makes it an attractive target for drugs that can be used to reduce the expression of ISCA1 and improve the diagnosis and prognosis of cancer.

Conclusion

In conclusion, ISCA1 is a protein that is involved in many different processes in the body, including cell adhesion, migration, and invasion. Its stability and involvement in multiple processes make it an attractive target for small molecules that can be used to inhibit its activity . In addition to its potential as a drug target, ISCA1 is also a potential biomarker for the diagnosis and prognosis of many different types of cancer. Further research is needed to fully understand the role of ISCA1 in cancer biology and to develop effective treatments.

Protein Name: Iron-sulfur Cluster Assembly 1

Functions: Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. Probably involved in the binding of an intermediate of Fe/S cluster assembly

More Common Targets